This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Astex Pharmaceuticals To Present At AACR Annual Meeting

Astex Pharmaceuticals, Inc. (NASDAQ: ASTX), a pharmaceutical company dedicated to the discovery and development of novel small molecule therapeutics, today announced the acceptance of fourteen abstracts for presentation at the American Association for Cancer Research (AACR) 2012 Annual Meeting. Oral and poster presentations will occur on March 31, April 1-3 in Chicago, IL.

Highlights include two oral presentations and two poster presentations on SGI-110, Astex’s novel second generation DNMT inhibitor, and a poster presentation on new data from the first in class dual IAP inhibitor program:

Saturday, March 31, 2012
 

3:55 – 4:30 pm CT
 

SGI-110
Invited Presentation
Scale-up and development of a process for a low-volume subcutaneous formulation of SGI-110, a potent hypomethylating agent
 

Monday, Apr 2, 2012

1:00 – 5:00 pm CT

IAP
Poster Presentation, Abstract # 2018
Discovery of potent dual inhibitors of both XIAP and cIAP1 using fragment based drug discovery
 

Monday, Apr 2, 2012

3:00 – 5:10 pm CT

SGI-110
Oral Presentation, Abstract #: LB-214
Interim results from a randomized Phase 1-2 first-in-human-(FIH) study of PK/PD guided escalating doses of SGI-110, a novel subcutaneous (SQ) second generation hypomethylating agent (HMA) in relapsed/refractory MDS and AML
 

Tuesday, Apr 3, 2012

1:00 – 5:00 pm CT

SGI-110
Poster Presentation, Abstract # 4077
Chemosensitizing effects of the novel, small molecule DNA methylation inhibitor SGI-110 in ovarian cancer
 

Tuesday, Apr 3, 2012

1:00 – 5:00 pm CT

SGI-110
Poster Presentation, Abstract # 4076
SGI-110, a novel subcutaneous (SQ) second generation DNA hypomethylating agent achieves improved pharmacodynamics (PD), safety and pharmacokinetics (PK) in comparison to IV decitabine in a non-human primate in vivo study
 

Nine additional presentations will highlight new data on the company’s drug development programs with AT13387 (HSP90 inhibitor), AT9283 (JAK/Aurora inhibitor), AT13148 (AGC Kinase inhibitor), MetAP2 inhibitors, PKM2 (Pyruvate Kinase) activators, and second generation PIM Kinase inhibitors. Select posters will be made available for viewing on the company’s website www.astx.com following the public presentation.

About Astex Pharmaceuticals

Astex Pharmaceuticals is dedicated to the discovery and development of novel small molecule therapeutics with a focus on oncology. The Company is developing a proprietary pipeline of novel therapies and is creating de-risked products for partnership with leading pharmaceutical companies. Astex Pharmaceuticals developed Dacogen® (decitabine) for Injection and receives significant royalties on global sales.

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
SYM TRADE IT LAST %CHG

Markets

DOW 17,757.91 +138.40 0.79%
S&P 500 2,077.42 +14.31 0.69%
NASDAQ 5,013.1230 +26.2560 0.53%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs